SIGYN trial - a randomized study comparing gemcitabine and mitomycin in intermediate-risk non-muscle-invasive bladder cancer
Not Applicable
- Conditions
- Intermediate-risk non-muscle-invasive bladder cancerCancer
- Registration Number
- ISRCTN87250222
- Lead Sponsor
- Skåne University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 340
Inclusion Criteria
1. Aged 18 years or above
2. Intermediate risk non-muscle invasive bladder cancer
3. Radically performed transurethral resection of the tumour
4. Written and verbal consent
Exclusion Criteria
1. Age below 18
2. Pregnancy
3. Allergy to gemcitabine or mitomycin
4. Chronic catheter
5. Severe incontinence
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method